Amylyx Pharmaceuticals, Inc. AMLX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $95.9M+7.0% | $90.4M-13.1% | $92.08M-27.0% | $93.47M-30.7% | $89.6M-36.3% | ||
| $63.37M-12.3% | $62.89M-45.0% | $64.59M-56.8% | $66.25M-63.3% | $72.26M-64.2% | ||
| $159.27M-30.5% | $153.29M-61.9% | $156.68M-66.6% | $196.73M-58.7% | $229.13M-52.2% | ||
| -$159.27M+30.9% | -$153.29M+51.3% | -$157.34M+42.2% | -$196.98M-10.8% | -$230.4M-183% | ||
| $9.2M-15.7% | $8.6M-31.7% | $7.42M-49.4% | $8.74M-43.2% | $10.91M-30.1% | ||
| —— | -$144.69M+52.1% | -$149.92M+41.8% | -$188.24M-15.9% | -$219.49M-234% | ||
| —— | $46K+112% | -$635K-132% | -$635K-118% | -$635K-112% | ||
| -$150.11M+31.4% | -$144.74M+52.0% | -$149.28M+42.5% | -$187.6M-13.1% | -$218.86M-208% | ||
| -$1.48+52.3% | -$1.53+65.5% | -$1.79+53.1% | -$2.49-1.6% | -$3.10-190% | ||
| -$158.8M+30.9% | -$152.77M+51.3% | -$156.76M+42.2% | -$196.3M-11.1% | -$229.66M-187% | ||
| -$159.27M+30.9% | -$153.29M+51.3% | -$157.34M+42.2% | -$196.98M-10.8% | -$230.4M-183% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Amylyx Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 100.0% and operating margin is -47349.8%, with a -45096.2% net margin.
- Where does Amylyx Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.